Recent advances in ophthalmology by Coleiro, Joseph A.
Malta Medical Journal    Volume 18   Issue 03   October 2006 7
Joseph A Coleiro
Review Article
Recent advances in ophthalmology
Joseph A Coleiro FRCSEd, FRCOphth
Consultant Ophthalmologist,
Fernbrae Private Hospital, Dundee, Scotland, UK
Email: jcoleiro@tiscali.co.uk
Keywords
Phacoemulsification; refractive surgery; lasik; phakic 
intraocular lens; photodynamic therapy.
These are exciting times for ophthalmology with 
developments in recent years taking place across a spectrum 
of eye diseases from the front to the back of the eye.
Cataract surgery
There has been a global increase in the rate of cataract 
surgery to meet the demand of an aging and longer living 
population. Like other branches of surgery, emphasis has been 
placed on smaller incision, often sutureless, phacoemulsification 
techniques using minimal local anaesthesia on a day care basis.
There have been modifications to the intraocular lens design and 
materials with a shift to the use of acrylic foldables. Multifocal 
lens systems have not so far gained universal appeal but there 
is a prospect of an accommodating lens. Prevention of haze and 
opacification of the posterior lens capsule remains a challenge 
with about 30% requiring the application of the Nd:Yag laser 
within 2 years. Simultaneous bilateral surgery is not the norm 
due to concern about the possibility of intraocular infection 
particularly with the popularity of corneal tunnel incisions. The 
protocol for prevention of this devastating complication has been 
undertaken in a multinational study under the auspices of the 
European Society of Cataract and Refractive Surgeons (ESCRS) 
with a recommendation for the placement of intracameral 
cefuroxime.1,2
Refractive surgery
The quest for dispensing with the wearing of lenses is 
not novel. An understandable desire to avoid dependence on 
external devices is what drives patients to seek surgery. Since 
the cornea is the most powerful ocular refracting surface, most 
procedures on offer attempt to modify its curvature. The earlier 
Russian advocated technique of radial keratotomy has been 
universally abandoned in favour of laser based procedures 
since the introduction of the excimer laser. With this argon 
fluoride laser, with a wavelength of 193 nm, corneal tissue can 
be removed with a high degree of precision. Early treatments 
by photo-refractive keratectomy with application of the laser 
after removing the central corneal epithelium were followed 
by pain, corneal haze lasting several months and unpleasant 
visual effects by light. 
These have now been replaced by treatments under a 
thin corneal flap produced by a microkeratome, laser in-situ 
keratomileusis (LASIK). Original nasal hinged flaps had a 
tendency to become displaced with blinking action; this has 
been overcome by a superiorly placed hinge. Cutting nerves 
on both sides however tends to produce a dry ocular surface 
requiring placement of temporary plugs into the lacrimal 
puncta and liberal use of lubricants. Interface problems 
such as diffuse lamellar keratitis are fortunately rare. The 
procedure can be tailored to treat increasing larger degrees of 
myopia, hypermetropia and any astigmatism. There is concern 
however about potential bulging of the cornea and even frank 
ectasia if too much tissue is ablated in excess of about half the 
corneal thickness (normally 550 microns).3 This has also been 
reported after photorefractive keratectomy for low myopia.4 
The introduction of a femtosecond laser, Intralase, produces 
a superior cut than can be made with a blade but is currently 
prohibitively expensive. A more superficial technique of LASEK 
has its advocates.
Higher degrees of myopia can be approached by procedures 
on the crystalline lens. Clear lens extraction with or without a 
low power implant is effectively cataract surgery in the absence 
of significant lens opacity. Alternatively an intraocular lens or 
contact lens may be introduced through a small incision and 
secured to the iris or wedged into the anterior chamber angle. 
There is a possibility of corneal touch or the development of lens 
opacities requiring cataract surgery and lens exchange. 
These refractive procedures are not without risk and can 
have unpredictable outcomes which may result in medico-legal 
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disputes; the medical defence organisations have accordingly 
raised the premiums for practitioners undertaking this type of 
surgery,
In search of the ideal pressure lowering agent
The late 1970s saw the introduction of ß-blocker drops as a 
first line treatment for open angle glaucoma by reducing aqueous 
formation. These have now been superseded by prostaglandin 
analogues which reduce the pressure by improving outflow. 
Both drugs may be used in combination in single preparation 
for improved effect5 and more acceptable compliance and 
minimising exposure to preservatives. Most prostaglandin 
type drugs produce darkening and elongation of the eyelashes, 
pigmentation of periorbital skin and occasionally the iris; these 
are more noticeable if applied to one eye only. However they 
have fewer systemic side effects.
There has been a fall in demand for glaucoma surgery 
which may be combined with simultaneous cataract extraction. 
Trabeculectomy introduced in 1972 became widely adopted 
but may fail due to propensity for fibrosis at the drainage site, 
particularly in darker races. Glaucoma surgery may be enhanced 
by application of antimetabolites such as mitomycin-C or 5-FU 
in selected cases or after failure of the first procedure.6  The use of 
valves with a plate anchored to the sclera and a tube protruding 
into the anterior chamber has become more acceptable and 
effective in recalcitrant cases.7 Standard glaucoma procedures 
often fail in black patients but improved results can be obtained 
by viscocanalostomy8 or non-perforating deep sclerectomy 
accompanied by a biosynthetic gel implant.9
Photodynamic therapy
Macular degeneration is the commonest cause of blindness 
in advancing years. The dry form is associated with increased 
pigmentation and gradual atrophy leading to loss of central vision. 
The wet form is accompanied by subretinal neovascularisation 
arising from the underlying vascular choroid. These fragile new 
vessels identified by fluorescein angiography can selectively take 
up verteporfin (Visudyne) given intravenously to a which a laser 
is applied for their eradication before a significant bleed occurs 
which inevitably produces disorganisation and fibrosis of this 
important part of the retina.10 Anti-vascular endothelial growth 
factor (VEGF) therapy with pegaptanib is also hopeful but has 
the disadvantage of requiring intravitreal injections every six 
weeks for about a year with attendant risks.11 Very few patients 
are likely to benefit; the availability of the drugs is limited by 
expense. Dietary factors have been identified; the addition of 
minerals such as zinc and selenium as well as antioxidant agents 
such as lutein and zeaxanthine help in retarding the progression 
of macular disease. Cessation of smoking is also advocated.
An artificial cornea?
Vision drops or becomes distorted when the cornea becomes 
hazy or opaque. The year 2005 saw the centenary of the first 
corneal graft from a human donor. Laboratory techniques have 
extended the viability of donor tissue but there is still a world 
wide shortage of available corneae. The major indication for a 
transplant in young patients is the presence of a conical cornea, 
a condition known as keratoconus, which may produce marked 
thinning beyond the scope of satisfactory contact lens fitting. Age 
related degeneration of the corneal endothelium or accelerated 
by cataract surgery resulting in decompensation is the major 
reason why patients come to surgery in the older age groups. 
Whereas a full thickness disc has been the norm, there is now a 
shift to lamellar techniques with a lower risk of graft rejection 
when the endothelium is healthy. Early trials in Perth, Australia 
on an artificial cornea Alphacor are encouraging.
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